卡瑞利珠单抗联合化疗药物热灌注对原发性肝癌PD-1/PD-L1信号通路的影响

doi:10.3969/j.issn.1006-6233.2023.11.033

Abstract
Figure/Table
References
Related Citation (11)

Download: PDF (1615 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the mechanism of action of camrelizumab combined with chemotherapy and hyperthermic perfusion in the treatment of primary liver cancer based on the PD-1/PD-L1 signaling pathway. Methods: Eighty patients with advanced primary hepatocellular carcinoma (PHC) treated in the hospital from February 2019 to March 2021 were randomly divided into two groups:a chemotherapy and hyperthermic perfusion group and an apatinib plus chemotherapy and hyperthermic perfusion group,each consisting of 40 patients.The chemotherapy and hyperthermic perfusion group received chemotherapy and hyperthermic perfusion treatment,while the apatinib plus chemotherapy and hyperthermic perfusion group received apatinib plus chemotherapy and hyperthermic perfusion treatment after the initial treatment.Short-term clinical efficacy was compared between the two groups.Flow cytometry was used to assess changes in tumor markers (CEA,AFP,AFP-L3) and T lymphocyte subsets.Liver function indexes (ALT,AST,TBIL,ALP) were compared.PD-1 and PD-L1 expression in peripheral blood were assessed,and the incidence of adverse reactions was compared.Kaplan-Meier survival analysis was conducted during patient follow-up to compare survival rates. Results: In the apatinib plus chemotherapy and hyperthermic perfusion group,short-term clinical efficacy and peripheral blood CD4⁺,CD8⁺,and CD4⁺/CD8⁺ ratio were higher compared to the chemotherapy and hyperthermic perfusion group.Levels of AFP,AFP-L3,CEA,ALT,AST,TBIL,ALP,PD-1,and PD-L1 expression in peripheral blood were lower in the apatinib combination group (P<0.05).The apatinib combination group had a lower incidence of pain and a higher survival rate compared to the chemotherapy and hyperthermic perfusion group (P<0.05). Conclusion: The combination of camrelizumab and chemotherapy and hyperthermic perfusion can activate T lymphocyte subsets by inhibiting the PD-1/PD-L1 signaling pathway,thereby improving the body's anti-tumor immune function,prolonging the survival period of patients,and reducing pain.This approach is worth promoting in clinical practice.

Key words： Primary liver cancer PD-1/PD-L1 signaling pathway Carrilizumab

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.11.033 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I11/1927

[1] Zhou H,Song T.Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J].Biosci Trends,2021,15(3):155-160.
[2] Li Z,Li Q,Wang X,et al.Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma:a systematic review and meta-analysis[J].Cancer Med,2021,10(23):8432-8450.
[3] Kumagai S,Koyama S,Itahashi K,et al.Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments[J].Cancer Cell,2022,40(2):201-218.
[4] Luo H,Lu J,Bai Y,et al.Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma:the ESCORT-1st randomized clinical trial[J].JAMA,2021,326(10):916-925.
[5] 徐金发,宋文灿,郑中显,等.国产细胞程序性死亡受体1抑制剂卡瑞利珠单抗联合阿帕替尼一线治疗中晚期原发性肝癌的疗效研究[J].中国全科医学,2022,25(26):3258-3262.
[6] Hu B,Yu M,Ma X,et al.IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment[J].Cancer Discov,2022,12(7):1718-1741.
[7] Yan Y,Zheng L,Du Q,et al.Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells[J].Cancer Immunol Immunother,2020,69(9):1891-1903.
[8] Rakke YS,Sprengers D,Kwekkeboom J,et al.Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma[J].Ann Transl Med,2020,8(23):1614.
[9] 杜尚云,翁莉,武敏.TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究[J].实用肝脏病杂志,2023,26(1):116-119.
[10] Guo Z,Zhang K,Wei X,et al.Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1,TIGIT,and CTLA-4 in esophageal squamous cell carcinoma[J].Leukoc Biol,2023,113(1):11-17.